In silico drug sensitivity predicts subgroup-specific therapeutics in medulloblastoma patients.

ABSTRACT: Medulloblastoma is the most common malignant pediatric brain tumor. Survival rates vary widely between subgroups, with an average overall survival of 70%. Recurrent medulloblastoma is highly aggressive, treatment-resistant, and usually fatal. In addition, current treatments are highly toxic to the developing brain and surviving patients suffer from lifelong side effects. Therefore, novel therapeutic options are urgently needed. To inform risk-based, personalized therapy, we developed a novel platform called DrugSeq, which allows predictions of drug sensitivities in patients across medulloblastoma subgroups. We used a perturbagen-response dataset to calculate transcriptional response signatures for each drug and compared this to patient medulloblastoma tumor gene expression. We then stratif

SUBMITTER: Jermakowicz AM 

PROVIDER: S-EPMC12660821 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature